tetano
Editor, Senior Moderator
Sci Rep
. 2022 Oct 10;12(1):16956.
doi: 10.1038/s41598-022-21223-2.
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
Aruni Jha[SUP] 1 [/SUP], Douglas Barker[SUP] 1 [/SUP], Jocelyne Lew[SUP] 2 [/SUP], Vinoth Manoharan[SUP] 2 [/SUP], Jill van Kessel[SUP] 2 [/SUP], Robert Haupt[SUP] 3 [/SUP], Derek Toth[SUP] 1 [/SUP], Matthew Frieman[SUP] 3 [/SUP], Darryl Falzarano[SUP] 2 4 [/SUP], Shantha Kodihalli[SUP] 5 [/SUP]
Affiliations
Abstract
In late 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into a worldwide pandemic. It has caused millions of hospitalizations and deaths, despite the use of COVID-19 vaccines. Convalescent plasma and monoclonal antibodies emerged as major therapeutic options for treatment of COVID-19. We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma. In this report the efficacy of COVID-HIGIV was evaluated in hamster and mouse models of SARS-CoV-2 infection. COVID-HIGIV treatment in both mice and hamsters significantly reduced the viral load in the lungs. Among COVID-HIGIV treated animals, infection-related body weight loss was reduced and the animals regained their baseline body weight faster than the PBS controls. In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation (NCT04910269, NCT04546581).
. 2022 Oct 10;12(1):16956.
doi: 10.1038/s41598-022-21223-2.
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
Aruni Jha[SUP] 1 [/SUP], Douglas Barker[SUP] 1 [/SUP], Jocelyne Lew[SUP] 2 [/SUP], Vinoth Manoharan[SUP] 2 [/SUP], Jill van Kessel[SUP] 2 [/SUP], Robert Haupt[SUP] 3 [/SUP], Derek Toth[SUP] 1 [/SUP], Matthew Frieman[SUP] 3 [/SUP], Darryl Falzarano[SUP] 2 4 [/SUP], Shantha Kodihalli[SUP] 5 [/SUP]
Affiliations
- PMID: 36216961
- DOI: 10.1038/s41598-022-21223-2
Abstract
In late 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into a worldwide pandemic. It has caused millions of hospitalizations and deaths, despite the use of COVID-19 vaccines. Convalescent plasma and monoclonal antibodies emerged as major therapeutic options for treatment of COVID-19. We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma. In this report the efficacy of COVID-HIGIV was evaluated in hamster and mouse models of SARS-CoV-2 infection. COVID-HIGIV treatment in both mice and hamsters significantly reduced the viral load in the lungs. Among COVID-HIGIV treated animals, infection-related body weight loss was reduced and the animals regained their baseline body weight faster than the PBS controls. In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation (NCT04910269, NCT04546581).